JP2013543378A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013543378A5 JP2013543378A5 JP2013530569A JP2013530569A JP2013543378A5 JP 2013543378 A5 JP2013543378 A5 JP 2013543378A5 JP 2013530569 A JP2013530569 A JP 2013530569A JP 2013530569 A JP2013530569 A JP 2013530569A JP 2013543378 A5 JP2013543378 A5 JP 2013543378A5
- Authority
- JP
- Japan
- Prior art keywords
- medicament
- hyperalgesia
- medicament according
- polypeptide
- allodynia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 45
- 208000004454 Hyperalgesia Diseases 0.000 claims 40
- 229920001184 polypeptide Polymers 0.000 claims 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims 20
- 208000035154 Hyperesthesia Diseases 0.000 claims 18
- 206010053552 allodynia Diseases 0.000 claims 16
- 230000037396 body weight Effects 0.000 claims 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 12
- 208000002193 Pain Diseases 0.000 claims 9
- 239000002775 capsule Substances 0.000 claims 9
- 230000002269 spontaneous effect Effects 0.000 claims 8
- 208000004983 Phantom Limb Diseases 0.000 claims 6
- 206010056238 Phantom pain Diseases 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 210000002966 serum Anatomy 0.000 claims 4
- 230000004071 biological effect Effects 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000012528 membrane Substances 0.000 claims 3
- 208000004296 neuralgia Diseases 0.000 claims 3
- 208000021722 neuropathic pain Diseases 0.000 claims 3
- 230000000508 neurotrophic effect Effects 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 230000035807 sensation Effects 0.000 claims 3
- 230000003442 weekly effect Effects 0.000 claims 3
- 108091035707 Consensus sequence Proteins 0.000 claims 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 239000002243 precursor Substances 0.000 claims 2
- 235000018102 proteins Nutrition 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 241000710929 Alphavirus Species 0.000 claims 1
- 241000701822 Bovine papillomavirus Species 0.000 claims 1
- 241000711573 Coronaviridae Species 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 206010024453 Ligament sprain Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 102100025695 Meteorin Human genes 0.000 claims 1
- 101710204352 Meteorin Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 241000288906 Primates Species 0.000 claims 1
- 241000687919 Rodinia Species 0.000 claims 1
- 241000700584 Simplexvirus Species 0.000 claims 1
- 208000010040 Sprains and Strains Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 210000001130 astrocyte Anatomy 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000005611 electricity Effects 0.000 claims 1
- 210000000604 fetal stem cell Anatomy 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 230000002518 glial effect Effects 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 210000001178 neural stem cell Anatomy 0.000 claims 1
- 231100000862 numbness Toxicity 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241000701447 unidentified baculovirus Species 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201070423 | 2010-10-01 | ||
| DKPA201070423 | 2010-10-01 | ||
| US39079110P | 2010-10-07 | 2010-10-07 | |
| US61/390,791 | 2010-10-07 | ||
| PCT/DK2011/050369 WO2012041328A1 (en) | 2010-10-01 | 2011-09-30 | Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016219822A Division JP6247734B2 (ja) | 2010-10-01 | 2016-11-10 | アロディニア、痛覚過敏、自発痛及び幻肢痛の処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013543378A JP2013543378A (ja) | 2013-12-05 |
| JP2013543378A5 true JP2013543378A5 (https=) | 2014-11-13 |
| JP6149226B2 JP6149226B2 (ja) | 2017-06-21 |
Family
ID=59278857
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013530569A Active JP6149226B2 (ja) | 2010-10-01 | 2011-09-30 | アロディニア、痛覚過敏、自発痛及び幻肢痛の処置 |
| JP2016219822A Active JP6247734B2 (ja) | 2010-10-01 | 2016-11-10 | アロディニア、痛覚過敏、自発痛及び幻肢痛の処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016219822A Active JP6247734B2 (ja) | 2010-10-01 | 2016-11-10 | アロディニア、痛覚過敏、自発痛及び幻肢痛の処置 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US8404642B2 (https=) |
| EP (1) | EP2621512B1 (https=) |
| JP (2) | JP6149226B2 (https=) |
| KR (1) | KR101886029B1 (https=) |
| CN (2) | CN108079279B (https=) |
| AU (1) | AU2011307488B2 (https=) |
| CA (1) | CA2813013C (https=) |
| ES (1) | ES2584068T3 (https=) |
| WO (1) | WO2012041328A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102164611B (zh) | 2008-07-24 | 2015-01-07 | Ns基因公司 | 生长因子metrnl的治疗用途 |
| JP6149226B2 (ja) | 2010-10-01 | 2017-06-21 | ホーバ セラピューティクス アンパルトセルスカブ | アロディニア、痛覚過敏、自発痛及び幻肢痛の処置 |
| CN107596346A (zh) | 2011-09-05 | 2018-01-19 | 霍巴治疗公司 | 异常性疼痛、痛觉过敏、自发性疼痛、和幻痛的治疗 |
| CN103685771A (zh) * | 2013-12-13 | 2014-03-26 | 苏州士丹尼信息技术有限公司 | 一种集成的信息交流系统 |
| CN107184956B (zh) * | 2016-03-14 | 2020-09-08 | 上海风劲生物医药科技有限公司 | Metrnl蛋白或基因在防治脓毒血症方面的应用 |
| WO2020163469A2 (en) | 2019-02-08 | 2020-08-13 | BioLegend, Inc. | METHODS FOR DETECTING METEORIN-β ACTIVITY |
| KR20240006581A (ko) | 2021-05-06 | 2024-01-15 | 호바 세라퓨틱스 에이피에스 | 화학요법-유도된 신경병성 통증의 예방 및 치료 |
| CA3239550A1 (en) | 2021-12-10 | 2023-06-15 | Kenneth Petersen | Treatment of nociceptive pain |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4352883A (en) | 1979-03-28 | 1982-10-05 | Damon Corporation | Encapsulation of biological material |
| US4353888A (en) | 1980-12-23 | 1982-10-12 | Sefton Michael V | Encapsulation of live animal cells |
| US4407957A (en) | 1981-03-13 | 1983-10-04 | Damon Corporation | Reversible microencapsulation of a core material |
| US5169637A (en) | 1983-03-24 | 1992-12-08 | The Liposome Company, Inc. | Stable plurilamellar vesicles |
| CA1237671A (en) | 1983-08-01 | 1988-06-07 | Michael W. Fountain | Enhancement of pharmaceutical activity |
| US4762915A (en) | 1985-01-18 | 1988-08-09 | Liposome Technology, Inc. | Protein-liposome conjugates |
| WO1987000201A1 (en) | 1985-07-05 | 1987-01-15 | Whitehead Institute For Biomedical Research | Epithelial cells expressing foreign genetic material |
| US4883666A (en) | 1987-04-29 | 1989-11-28 | Massachusetts Institute Of Technology | Controlled drug delivery system for treatment of neural disorders |
| EP0378576B1 (en) | 1987-09-11 | 1995-01-18 | Whitehead Institute For Biomedical Research | Transduced fibroblasts and uses therefor |
| US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
| US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
| US5106627A (en) | 1987-11-17 | 1992-04-21 | Brown University Research Foundation | Neurological therapy devices |
| US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
| US5156844A (en) | 1987-11-17 | 1992-10-20 | Brown University Research Foundation | Neurological therapy system |
| DE3829766A1 (de) | 1988-09-01 | 1990-03-22 | Akzo Gmbh | Verfahren zur herstellung von membranen |
| DE3829752A1 (de) | 1988-09-01 | 1990-03-22 | Akzo Gmbh | Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration |
| US5082670A (en) | 1988-12-15 | 1992-01-21 | The Regents Of The University Of California | Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system |
| US5185154A (en) | 1989-02-02 | 1993-02-09 | Liposome Technology, Inc. | Method for instant preparation of a drug containing large unilamellar vesicles |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5084350A (en) | 1990-02-16 | 1992-01-28 | The Royal Institution For The Advance Of Learning (Mcgill University) | Method for encapsulating biologically active material including cells |
| US5618531A (en) | 1990-10-19 | 1997-04-08 | New York University | Method for increasing the viability of cells which are administered to the brain or spinal cord |
| US5219990A (en) | 1991-01-28 | 1993-06-15 | Biogen, Inc. | Papillomavirus e2 trans-activation repressors |
| CA2109085C (en) | 1991-04-25 | 2003-03-11 | Keith E. Dionne | Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products |
| ATE226250T1 (de) | 1992-04-30 | 2002-11-15 | Innogenetics Nv | Polypeptide und peptide dafür kodierende nukleinsaüre und ihre verwendung im zusammenhang mit tumortherapie, entzündung oder immunology |
| WO1994012158A1 (en) | 1992-12-02 | 1994-06-09 | Alkermes Controlled Therapeutics, Inc. | Controlled release growth hormone containing microspheres |
| US5512600A (en) | 1993-01-15 | 1996-04-30 | Massachusetts Institute Of Technology | Preparation of bonded fiber structures for cell implantation |
| AU688776B2 (en) | 1993-06-23 | 1998-03-19 | Brown University Research Foundation | Method and apparatus for sealing implantable, membrane encapsulation devices |
| ATE218893T1 (de) | 1993-08-12 | 2002-06-15 | Neurotech Sa | Biokompatible immunoisolatorische kapseln, die genetisch veränderte zellen enthalten |
| EP0804249A2 (en) | 1994-03-15 | 1997-11-05 | Brown University Research Foundation | Polymeric gene delivery system |
| US5550050A (en) | 1994-04-15 | 1996-08-27 | Cytotherapeutics, Inc. | Method for implanting encapsulated cells in a host |
| US5656465A (en) | 1994-05-04 | 1997-08-12 | Therion Biologics Corporation | Methods of in vivo gene delivery |
| DK0779806T3 (da) | 1994-09-09 | 2000-11-27 | Takeda Chemical Industries Ltd | Præparat til forsinket frigivelse indeholdende et metalsalt af et peptid |
| US5677158A (en) | 1995-06-07 | 1997-10-14 | Research Foundation Of State University Of New York | In vitro packaging of adeno-associated virus DNA |
| NZ310644A (en) | 1995-06-07 | 1999-08-30 | Alkermes Inc | Composition for sustained release of human growth hormone |
| ZA965368B (en) | 1995-07-14 | 1997-01-14 | Novo Nordisk As | A pharmaceutical formulation |
| US5904144A (en) | 1996-03-22 | 1999-05-18 | Cytotherapeutics, Inc. | Method for treating ophthalmic diseases |
| US6027721A (en) | 1996-05-20 | 2000-02-22 | Cytotherapeutics, Inc. | Device and method for encapsulated gene therapy |
| US6054142A (en) | 1996-08-01 | 2000-04-25 | Cyto Therapeutics, Inc. | Biocompatible devices with foam scaffolds |
| US6303136B1 (en) | 1998-04-13 | 2001-10-16 | Neurotech S.A. | Cells or tissue attached to a non-degradable filamentous matrix encapsulated by a semi-permeable membrane |
| US6683058B1 (en) | 1998-04-15 | 2004-01-27 | Regents Of The University Of California | Methods for therapy of neurodegenerative disease of the brain |
| DE69929600T2 (de) | 1998-05-27 | 2006-09-07 | Avigen Inc., Alameda | Konvektion-erhöhte verabreichung aadc-kodierende aav vektoren |
| US20020055467A1 (en) * | 1998-07-06 | 2002-05-09 | Johansen Teit E. | Novel neurotrophic factors |
| US6361771B1 (en) | 1999-04-06 | 2002-03-26 | Neurotech S.A. | ARPE-19 as a platform cell line for encapsulated cell-based delivery |
| AU7452300A (en) | 1999-10-01 | 2001-05-10 | Kyowa Hakko Kogyo Co. Ltd. | Shear stress-response dna |
| WO2001039786A2 (en) | 1999-11-30 | 2001-06-07 | Innogenetics N.V. | New uses of suppressive macrophage activation factors |
| CA2395872A1 (en) | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| CA2395676A1 (en) | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| CA2399776A1 (en) | 2000-02-03 | 2001-08-09 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| CA2403901A1 (en) | 2000-05-02 | 2001-11-08 | Human Genome Sciences, Inc. | 29 human secreted proteins |
| US20020037281A1 (en) | 2000-05-26 | 2002-03-28 | Davidson Beverly L. | Methods of transducing neural cells using lentivirus vectors |
| US6555674B2 (en) | 2000-08-09 | 2003-04-29 | Nsgene A/S | JeT promoter |
| EP1395279B1 (en) | 2001-03-28 | 2011-10-05 | Biogen Idec MA Inc. | Use of neublastin polypeptides for treating neuropathic pain |
| AU2002364968A1 (en) | 2001-12-21 | 2003-09-02 | Diadexus, Inc. | Compositions and methods relating to hepatic specific genes and proteins |
| WO2004035732A2 (en) | 2002-08-29 | 2004-04-29 | Five Prime Therapeutics, Inc. | Human polypeptides encoded by polynucleotides and methods of their use |
| US20050203142A1 (en) * | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
| US20050208500A1 (en) | 2003-03-04 | 2005-09-22 | Erlander Mark G | Signatures of ER status in breast cancer |
| PL1745069T3 (pl) * | 2004-03-30 | 2009-10-30 | Nsgene As | Zastosowanie terapeutyczne czynnika wzrostu NSG33 |
| ES2375481T3 (es) | 2004-03-30 | 2012-03-01 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Anticuerpos biespecíficos para elegir como diana células que participan en reacciones de tipo alérgico, composiciones y usos de los mismos. |
| US20070161696A1 (en) * | 2004-04-23 | 2007-07-12 | Zeldis Jerome B | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
| WO2006110593A2 (en) * | 2005-04-07 | 2006-10-19 | Macrogenics, Inc. | Biological targets for the diagnosis, treatment and prevention of cancer |
| EP1883446B8 (en) | 2005-05-17 | 2017-11-15 | Gloria Therapeutics Sarl | An implantable therapy system for treating a living being with an active factor |
| JP2009513584A (ja) | 2005-10-28 | 2009-04-02 | エヌエスゲーネ・アクティーゼルスカブ | Ｇｄｎｆの送達のための移植可能な生体適合性免疫隔離ビヒクル |
| JP2009527576A (ja) | 2006-02-24 | 2009-07-30 | ネオフアーム・インコーポレイテツド | カルジオリピン調製の方法および工程 |
| TWI501774B (zh) | 2006-02-27 | 2015-10-01 | Biogen Idec Inc | 神經性病症之治療 |
| WO2008136541A1 (en) * | 2007-05-02 | 2008-11-13 | Snu R&Db Foundation | Angiogenesis inhibitor comprising meteorin as an active ingredient |
| KR100823156B1 (ko) * | 2007-05-02 | 2008-04-22 | 재단법인서울대학교산학협력재단 | 메테오린을 유효성분으로 포함하는 혈관신생 억제제 |
| WO2009069764A1 (ja) * | 2007-11-30 | 2009-06-04 | National University Corporation Chiba University | オピオイド鎮痛剤 |
| CN102164611B (zh) * | 2008-07-24 | 2015-01-07 | Ns基因公司 | 生长因子metrnl的治疗用途 |
| WO2010021882A2 (en) * | 2008-08-19 | 2010-02-25 | Janssen Pharmaceutica Nv | Cold menthol receptor antagonists |
| CA2739416C (en) * | 2008-09-03 | 2017-10-31 | Arbor Vita Corporation | Agents and methods for treatment of pain |
| TW201031650A (en) * | 2008-12-02 | 2010-09-01 | Organon Nv | 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione |
| JP6149226B2 (ja) | 2010-10-01 | 2017-06-21 | ホーバ セラピューティクス アンパルトセルスカブ | アロディニア、痛覚過敏、自発痛及び幻肢痛の処置 |
-
2011
- 2011-09-30 JP JP2013530569A patent/JP6149226B2/ja active Active
- 2011-09-30 CN CN201810021543.XA patent/CN108079279B/zh active Active
- 2011-09-30 CN CN2011800580444A patent/CN103269708A/zh active Pending
- 2011-09-30 WO PCT/DK2011/050369 patent/WO2012041328A1/en not_active Ceased
- 2011-09-30 ES ES11773666.0T patent/ES2584068T3/es active Active
- 2011-09-30 CA CA2813013A patent/CA2813013C/en active Active
- 2011-09-30 AU AU2011307488A patent/AU2011307488B2/en active Active
- 2011-09-30 EP EP11773666.0A patent/EP2621512B1/en active Active
- 2011-09-30 KR KR1020137011264A patent/KR101886029B1/ko active Active
- 2011-10-03 US US13/251,630 patent/US8404642B2/en active Active
-
2013
- 2013-03-14 US US13/828,362 patent/US8815810B2/en active Active
-
2014
- 2014-08-22 US US14/466,047 patent/US9314502B2/en active Active
-
2016
- 2016-11-10 JP JP2016219822A patent/JP6247734B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013543378A5 (https=) | ||
| ES2238969T3 (es) | Neurotoxinas presinapticas para el tratamiento de cefaleas migrañosas. | |
| RU2593960C2 (ru) | Фармацевтическая композиция для лечения метаболического синдрома | |
| EP1993589B1 (en) | Treatments for neurological disorders | |
| JP2014526441A5 (https=) | ||
| JP6403062B2 (ja) | 組織修復活性組成物及びその利用 | |
| EP3610905A1 (en) | Extended release of neuregulin for treating heart failure | |
| CN103372199A (zh) | 一种预防和治疗神经退行性疾病的新型脑部靶向制剂 | |
| EP1846022B1 (en) | Methods for treating adhesive capsulitis | |
| JP2014529408A5 (https=) | ||
| AU2016213899A1 (en) | Compositions and methods for treatment during non-acute periods following cns neurological injury | |
| McFarlane | Antidiabetic medications and weight gain: implications for the practicing physician | |
| US20070154534A1 (en) | Use of secretin in the treatment of schizophrenia | |
| EP3402505B1 (en) | Pharmaceutical formulations for the treatment of diabetes | |
| US10160791B2 (en) | Protamine in treatment of neuronal injuries | |
| CN113956334B (zh) | 一种棕色脂肪细胞分泌肽及其衍生物在肥胖防治中的应用 | |
| CN114126636B (zh) | 用于治疗胰岛素缺乏病症的组合物 | |
| US8895505B2 (en) | Method of treatment of type 2 diabetes | |
| CN111249300B (zh) | 褪黑素联合甲钴胺在治疗糖尿病创面愈合障碍中的应用 | |
| JP2004508419A (ja) | 心電図のｑｔ間隔の短縮 | |
| AU2014271188A1 (en) | Treatment of neurological and other disorders | |
| Cefalu et al. | Clinical research observations with use of exubera in patients with type 1 and 2 diabetes | |
| Owayez et al. | New Dosage Form of Insulin | |
| CN112023027B (zh) | 胸腺素或其衍生物的应用和治疗快感缺乏型抑郁症的药物 | |
| CN101766811A (zh) | 艾塞那肽或其类似物在制备治疗或预防糖尿病合并脑梗塞药物中的用途 |